@article{articlefa10006a,
title   = {Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial},
author = {Prince, H. Miles and Kim, Youn H. and Horwitz, Steven M. and Dummer, Reinhard and Scarisbrick, Julia and Quaglino, Pietro and Zinzani, Pier Luigi and Wolter, Pascal and Sanches, Jose A. and Ortiz-Romero, Pablo L. and Akilov, Oleg E. and Geskin, Larisa and Trotman, Judith and Taylor, Kerry and Dalle, Stephane and Weichenthal, Michael and Walewski, Jan and Fisher, David and Dréno, Brigitte and Stadler, Rudolf and Feldman, Tatyana and MKuzel, Timothy and Wang, Yinghui and Palanca-Wessels, Maria Corinna and Zagadailov, Erin and Trepicchio, William L and Zhang, Wenwen and Lin, Hui-Min and Liu, Yi and Huebner, Dirk and Little, Meredith and Whittaker, Sean and Duvic, Madeleine},
year = {2017},
doi = {10.1016/S0140-6736(17)31266-7},
journal   = {Lancet}
}